Combining Antibody-Drug Conjugates and Immunotherapy: mechanistic insights and clinical observations

Combining Antibody-Drug Conjugates and Immunotherapy: mechanistic insights and clinical observations

Monday, March 29, 2021 4:20 PM to 4:40 PM · 20 min. (Africa/Abidjan)
Antibodies
Armed antibodies
Presentation

Information

  • MMAE-based ADCs have demonstrated the potential to change the natural history of multiple cancers
  • MMAE, the cytotoxic payload, has been shown to induce immunogenic cell death
  • Combining MMAE-based ADCs with immunotherapy has the promise of augmenting the benefit of each of these therapies

Nancy Whiting, Executive Vice President, Development, Seattle Genetics 

Log in